Tegoprazan combined with minocycline dual therapy versus bismuth-containing quadruple therapy for Helicobacter pylori eradication:a randomized controlled trial
ZHANG Ju
LI Jie
LI Denghua
ZHU Xiaojing
GUO Qiqi
LIU Yuhao
ZHANG Yanpeng
SHI Yongquan
Abstract：Objective To explore the efficacy and safety of the tegoprazan-minocycline(TM)dual therapy in eradicating Helicobacter pylori(Hp).Methods In this prospective randomized controlled trial,initial Hp-infected patients were randomly assigned in a 1∶1 ratio to the TM group and the bismuth-containing quadruple therapy(BQT)group,with a treatment course of 14 d for both groups.The primary endpoint was the eradication rate of Hp,while secondary endpoints included the incidence of adverse events and patient compliance.The therapeutic effect was evaluated by intention-to-treat(ITT)analysis and per-protocol(PP)analysis.Results In the ITT analysis,the eradication rate was 73.1％(76/104)in the TM group and 72.1％(75/104)in the BQT group,and the difference was not statistically significant(P=0.876).In the PP analysis,the eradication rate was 81.7％(76/93)in the TM group and 87.2％(75/86)in the BQT group,and the difference was not statistically significant(P=0.312).The total incidence of adverse events in the TM group was lower than that in the BQT group(21.2％vs 43.3％,P＜0.001).The compliance rates of both groups were 97.1％(P=1.000).Conclusion In the treatment-naive population with Hp infection in the Xi'an region,the eradication efficacy of the TM dual therapy is generally similar to that of BQT.Moreover,the TM group experiences fewer overall adverse events and demonstrates compliance comparable to that of the BQT group.However,the absolute eradication rates in both groups do not reach the ideal level for empirical therapy,suggesting that TM is not yet suitable as a routine empirical alternative in this region.Its clinical value still requires further validation in larger-sample,multicenter studies and those stratified by drug susceptibility.
Keywords：Helicobacter pyloritegoprazanminocyclineamoxicillinclarithromycindual therapydrug resistanceeradication therapy
Publication Date：2026-06-30
Online Publishing Date：2026-08-26(First online date of this platform, not the publication date of the document)
Pages：6( 835-840 )